Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $3,569.00 |
|---|---|
| Enterprise Value | $532,101.00 |
| Earnings per Share | $0.02 |
| Beta | -0.43 |
| Outstanding Shares | 17,845,732 |
| P/E Ratio | 0.01 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.16 |
| Enterprise Value to EBIT | 0.8 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 1.8 |
| Debt to Equity | 0.2 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company was founded on February 28, 2002 and is headquartered in Tianjin, China.